Back to Newsroom

Immunexpress Announces Presentation at the American Thoracic Society International Conference on the Validation of SeptiCyte™ Lab

SEATTLE, May 11, 2016 — Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced that data from the VENUS trial validating SeptiCyte™ Lab as a novel immune response assay to distinguish between SIRS and sepsis in critically ill patients will be presented at the upcoming American Thoracic Society International Conference on May 18 in San Francisco.

 

Read more here.